NESS ZIONA, Israel, April 18, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that management will participate in the BMO-sponsored Class of 2018 Biotech IPOs Investor Day taking place in New York, NY.
Dr. Alon Seri-Levy, Chief Executive Officer, will provide a business overview and update on the Company’s pipeline programs on Friday, April 26th at 10:30 a.m. ET.
A live audio webcast of the presentation will be available in the Investors/Events & Presentations section of the Sol-Gel Technologies website at http://www.sol-gel.com. A webcast replay will also be available on this website shortly after conclusion of the event for 30 days.
About Sol-Gel Technologies
Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel’s current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. For additional information, please visit www.sol-gel.com.
For further information, please contact:
Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433
Investor Contact:
Patricia L. Bank
Westwicke, an ICR Company
+1-415-513-1284
[email protected]
Source: Sol-Gel Technologies Ltd.
